Skip to main content
OpenTrials
Completed

NCT Number: NCT01636453

The Penumbra Liberty Trial: Safety and Effectiveness in the Treatment of Wide-Neck Intracranial Aneurysms

To assess the safety and effectiveness of the Penumbra Liberty Stent System as adjunctive treatment to embolic coils for wide-neck, saccular, intracranial aneurysms in the internal carotid artery (ICA). The Liberty Stent System is an implantable device comprised of a stent and delivery system designed as an adjunct to embolic coils in the treatment of wide-neck, saccular, intracranial aneurysms. It has three components: an implant, an introducer sheath and a delivery wire assembly. The implant component is made of superelastic and biocompatible nitinol tubular material. Patients presenting with wide-neck, saccular, intracranial aneurysms in the internal carotid artery (ICA) from the cavernous segment to the carotid terminus (including the paraclinoid, ophthalmic, hypophyseal and posterior communicating segments) will receive stent assisted coiling by the Penumbra Liberty Stent with any approved embolic coils currently on the market. Wide-neck aneurysms are defined by a neck ≥4mm or a dome-to-neck ratio <2. Each patient will be followed and assessed for 2, 6 and 12 months after enrollment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Wide-neck, Saccular Intracranial Aneurysms Aneurysm Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Intracranial Aneurysm Intracranial Arterial Diseases Nervous System Diseases Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Swedish Medical Center, Denver, Colorado, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • At least 18 years old
  • A wide-neck intracranial saccular aneurysm with a neck ≥ 4mm or a dome to neck ratio <2 in the ICA from the cavernous segment to the carotid terminus (including the paraclinoid, ophthalmic, hypophyseal and posterior communicating segments)
  • Life expectancy > 12 months
  • Signed Informed Consent

Exclusion criteria

  • Females who are pregnant or intend to become pregnant during the study. (Females of child-bearing potential must have a urinary pregnancy test within 7 days of enrollment)
  • Extradural aneurysms
  • Known multiple untreated cerebral aneurysms at study entry
  • Recent history of subarachnoid hemorrhage, intracranial hemorrhage, or major surgery within one month of enrollment
  • Admission platelet <50,000 or any known hemorrhagic diathesis, coagulation deficiency, or on oral anticoagulant therapy with an INR >3.0
  • Contraindication to angiography such as elevated creatinine or known allergy to angiographic contrast
  • Contraindication to CT and/or MRI scans
  • Known allergy to the metal component of the Penumbra Liberty Stent System
  • Evidence of active infection (WBC >10x109 /L)
  • Any medical conditions that will not allow the necessary follow-up for this study (e.g., pre-existing neurological or psychiatric diseases)
  • Current substance-abuse /illicit drug use
  • Angiographic evidence of an arterial stenosis proximal to the target lesion that could prevent device deployment
  • Contraindications to study medications (heparin, aspirin, clopidogrel, and radiographic contrasts)

Treatment and study plan

Stent assisted coiling with the Liberty Stent

Device

Patients are implanted with the Liberty Stent as an assist to embolic coiling of their wide-neck, saccular, intracranial aneurysms and follow for 12 months

Primary outcomes

  1. Number of Participants With Raymond Class I Complete Obliteration at 12 Months

    Time frame: At 12 months post-implant

    Complete aneurysmal obliteration is defined by the method of Raymond et al. (Class I) (Stroke 2001;32:1998-2004).

  2. Number of Neurological Deaths or Major Ipsilateral Strokes at 12 Months Post Treatment.

    Time frame: At 12 months post-implant

Secondary outcomes

  1. Number of Ipsilateral Ischemic Strokes

    Time frame: At 12 months post-implant

    Defined as episodes of focal or global neurological dysfunction due to brain or retinal infarction in the same hemisphere of the target aneurysm with signs and symptoms that persist for 24 hours or longer. When appropriate, non contrast CT scans will be used to eliminate hemorrhagic strokes

  2. Number of Participants With Device-related Serious Adverse Events

    Time frame: During the procedure

    The number of participants with device-related Serious Adverse Events as a measure of safety of the procedure and device. The FDA definitions for Serious Adverse Events are used.

  3. Number of Device Deployment Failures

    Time frame: During the procedure

    Defined by the failure of the device to deploy or failure to correctly position the device over the aneurysm

  4. Number of Device Migrations

    Time frame: 12 months post-implant

    Migration is defined as movement of the Liberty stent by more than 5 mm as documented by the 12 month angiogram when compared to its immediate post-implant position.

  5. Number of Participants With Aneurysm Raymond Class I Occlusion Grading

    Time frame: At 12 months post-implant

    Raymond Class I Occlusion grading defined as complete obliteration of the aneurysm at 12 months.

  6. Number of Intracranial Hemorrhages

    Time frame: At 12 months post-implant

    Inclusive of subarachnoid, intraventricular or intraparenchymal hemorrhages (symptomatic or asymptomatic). Symptomatic is defined as a 4 point or more increase in the National Institutes of Health Stroke Scale (NIHSS) from baseline. The NIHSS ranges from 1 to 42, with higher scores indicating greater severity of stroke.

  7. Number of Participants With Functional Outcome as Defined by the Modified Rankin Scale (mRS) 0-2

    Time frame: At 12 months post-implant

    The Modified Rankin Scale measures functional ability on a scale from 0-5, with 0 indicating no symptoms at all and 5 indicating severe disability.

  8. All Cause Mortality (Number of Deaths From Any Cause)

    Time frame: At 12 months post-implant

  9. Number of Retreatments

    Time frame: At 12 months post-implant

    Defined as any intervention after the completion of the initial stent assisted coiling procedure

  10. Number of Participants Who Experienced Device Patency

    Time frame: at 12 months post-implant

    Device patency (stenosis) at 12 months

  11. Number of Participants Who Experienced Aneurysm Recanalization

    Time frame: At 12 months post-implant

Sponsors and collaborators

Lead sponsor

Penumbra Inc.

Industry

Registry information

Important dates

Study start
2012
Primary completion
2016
Study completion
2016
First posted
Jul 10, 2012
Registry last updated
Aug 23, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.